AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service
Recruiting
- Conditions
- Asthma
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 425
- Registration Number
- NCT06261567
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Observational Study Protocol: LIVER-R
Recruiting
- Conditions
- Hepatobiliary Cancers
- Interventions
- Other: Durvalumab-based combination therapies in observational study setting
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4490
- Registration Number
- NCT06252753
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
Phase 3
Completed
- Conditions
- Asthma, Exercise-Induced
- Interventions
- Drug: Budesonide/albuterol metered-dose inhaler 160/180 μgDrug: Placebo metered-dose inhaler
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 64
- Registration Number
- NCT06245551
- Locations
- 🇷🇺
Research Site, Ulyanovsk, Russian Federation
Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations
Recruiting
- Conditions
- Non-small-cell Lung Cancer
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT06245837
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
A Study to Assess Multidomain Endpoints of an ECG Patch
Recruiting
- Conditions
- Acute Decompensated Heart Failure
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 80
- Registration Number
- NCT06243029
- Locations
- 🇬🇧
Research Site, Leicester, United Kingdom
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 96
- Registration Number
- NCT06238466
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Brazilian Reality of Hepatocellular Carcinoma
Completed
- Conditions
- Hepatocellular CarcinomaHepatocellular Carcinoma Stage IIIHepatocellular Carcinoma Stage IHepatocellular Carcinoma by BCLC StageHepatocellular Carcinoma Stage II
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 300
- Registration Number
- NCT06230328
- Locations
- 🇧🇷
Research Site, Vitoria, Brazil
Trastuzumab-deruxtecan in Patients With Triple-negative Metastatic HER2-Low Breast Cancer: Real-world Experience in Brazil
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2
- Registration Number
- NCT06231693
- Locations
- 🇧🇷
Research Site, São Paulo, Brazil
A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
Phase 1
Active, not recruiting
- Conditions
- Solid Tumor, AdultNon-small Cell Lung CancerColorectal CarcinomaEndometrial CancerPancreatic Ductal AdenocarcinomaKRAS G12D
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT06218914
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Phase 2
Recruiting
- Conditions
- Gastric CancerGastroesophageal Junction CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT06219941
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath